347 reports of this reaction
0.6% of all NYSTATIN reports
#68 most reported adverse reaction
PULMONARY EMBOLISM is the #68 most commonly reported adverse reaction for NYSTATIN, manufactured by Padagis US LLC. There are 347 FDA adverse event reports linking NYSTATIN to PULMONARY EMBOLISM. This represents approximately 0.6% of all 59,130 adverse event reports for this drug.
NYSTATIN has an overall safety score of 82 out of 100. Patients taking NYSTATIN who experience pulmonary embolism should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
PULMONARY EMBOLISM is a less commonly reported adverse event for NYSTATIN, but still significant enough to appear in the safety profile.
In addition to pulmonary embolism, the following adverse reactions have been reported for NYSTATIN:
The following drugs have also been linked to pulmonary embolism in FDA adverse event reports:
PULMONARY EMBOLISM has been reported as an adverse event in 347 FDA reports for NYSTATIN. This does not prove causation, but indicates an association observed in post-market surveillance data.
PULMONARY EMBOLISM accounts for approximately 0.6% of all adverse event reports for NYSTATIN, making it a notable side effect.
If you experience pulmonary embolism while taking NYSTATIN, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.